Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.37 |
| ▸ | MVD | P53602 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346609 | 0.97 | FDPS (0.47) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL28334675 | 0.87 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL28196041 | 0.84 | FDPS (0.60) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL1763245 | 0.84 | — | — | |
| Triphosphate SCHEMBL18714 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL15555988 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL25284822 | 0.81 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL11149492 | 0.81 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL9632051 | 0.81 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL22717549 | 0.81 | FDPS (0.64) | FDPSBLMTDP1BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008274-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7790735-B2 | Methanocarba cycloalkyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-09-07 | — | — | US | disclosed |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | Govt of the U.S.A., represented by the Secretary, Dept of Health & Human Services (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1252160-B1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7087589-B2 | Methanocarba cycloakyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-08 | — | — | US | disclosed |
| US-7084128-B2 | Method for reducing intraocular pressure | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-6881725-B2 | Method for treating pain | INSPIRE PHARMACEUTICALS INC. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, THE, REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2003-11-20 | — | — | US | disclosed |
| US-20030186928-A1 | Method for reducing intraocular pressure | INSPIRE PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| EP-1348466-A2 | Method for treating pain with adenosine-tetraphosphates | Inspire Pharmaceuticals, Inc. (US) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030158147-A1 | Method for treating pain | INSPIRE PHARMACEUTICALS INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | PETERSON WARD M (US) | 2003-07-03 | — | — | US | disclosed |
| EP-1252160-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051490-A1 | METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | P2RY1, ADORA1, ADORA2A | FDPS 1325/4885BLM 2106/4885TDP1 967/4885 |
| US-20030125299-A1 | Method for treating or preventing inflammatory diseases | ADORA2B, ADORA2A, P2RY2 | FDPS 932/4885BLM 610/4885TDP1 2675/4885 |
| US-20030158147-A1 | Method for treating pain | P2RX2, P2RX3, P2RX5 | FDPS 582/4885BLM 2787/4885TDP1 496/4885 |
| US-20060270629-A1 | Methanocarba cycloalkyl nucleoside analogues | ADORA2A, ADORA1, ADORA2B | FDPS 1891/4885BLM 2138/4885TDP1 1221/4885 |
| US-20030186928-A1 | Method for reducing intraocular pressure | P2RY1, P2RY11, P2RY6 | FDPS 364/4885BLM 1141/4885TDP1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.